-
Product Insights
New![]()
RS Cogeneration Plant
RS Cogeneration Plant is a thermal project located in Louisiana, United States. The project is owned by RS Cogen, LLC.. The project came online in 2002. Empower your strategies with our RS Cogeneration Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
New![]()
RS & W Drift Mine
The RS & W Drift Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our RS & W Drift Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
New![]()
Sopros do RS Offshore Wind Project
Sopros do RS Offshore Wind Project is an offshore wind project located in South Atlantic Ocean, Brazil. The project is owned and being developed by TotalEnergies SE. The project is expected to come online in 2029. Empower your strategies with our Sopros do RS Offshore Wind Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
New![]()
Elektroprivreda RS – Mrsovo Hydropower Plant – Republic of Srspka
Equip yourself with the essential tools needed to make informed and profitable decisions with our Elektroprivreda RS – Mrsovo Hydropower Plant – Republic of Srspka report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of...
-
Company Insights
New![]()
Innovation and Patenting activity of RS Group plc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of RS Group plc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of RS Technologies Co., Ltd. Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of RS Technologies Co., Ltd. Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RS-8001 in Premenstrual Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RS-8001 in Premenstrual Syndrome Drug Details:RS-8001 (pyridoxamine) is under development for the treatment of premenstrual syndrome,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RS-1805 in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RS-1805 in Ulcerative Colitis Drug Details:RS-1805 is under development for the treatment of inflammatory bowel diseases...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RS-2102 in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RS-2102 in Atopic Dermatitis (Atopic Eczema) Drug Details: RS-2102 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RS-1805 in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RS-1805 in Crohn's Disease (Regional Enteritis) Drug Details:RS-1805 is under development for the treatment of inflammatory...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.